

## PRESS RELEASE

Stockholm, Sweden, 31 May 2017



### **Sobi™ discloses payments to the healthcare professionals and healthcare organisations to increase transparency**

[Swedish Orphan Biovitrum AB \(publ\)](#) (Sobi™) today announces that the company has made all payments and transfers of value to healthcare professionals and organisations from 2016 publicly available\*, including sponsorships to attend meetings, grants and donations, speaker fees, consultancy and advisory boards in accordance with the European Federation of Pharmaceutical Industries and Associations (EFPIA) Disclosure Code. The information is made available on [Sobi's corporate web site](#), starting 31 May 2017.

In the rare disease community collaboration between authorities, healthcare professionals, companies and patient organisations has always been a cornerstone in the development of new and better treatments. Increased transparency provides a strong basis for continued collaboration and can positively impact the quality of research, development and manufacturing across the industry.

“Transparency is an integral part of driving a sustainable business and our quality work supporting the high integrity standards that patients, prescribers, budget holders and other stakeholders expect. The EFPIA disclosure code is an important initiative to build trust for and within our industry,” said Lars Dreiøe, SVP, Chief Quality and Compliance Officer at Sobi. “Dialogue and interaction between healthcare professionals and organisations is vital when it comes to building sustainable value to rare disease patients and rare disease communities around the world.”

*\*Date for final publication in all EU countries is 30 June 2017. The data will be continuously updated to this date.*

---

#### **About EFPIA Disclosure Code**

The EFPIA (European Federation of Pharmaceutical Industries and Associations) Disclosure Code is a formal code of conduct that requires all EFPIA member companies and companies which are members of EFPIA member associations to disclose transfers of value to healthcare professionals (HCPs) and healthcare organisations (HCOs). The information is published on a public platform, which could be on the company's own website or a central platform combing data from different companies.

#### **About Sobi™**

Sobi is an international specialty healthcare company dedicated to rare diseases. Sobi's mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. Sobi also markets a portfolio of specialty and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and about 760 employees. The share (STO: SOBI) is listed on Nasdaq Stockholm. More information is available at [www.sobi.com](http://www.sobi.com) or [www.sobi.com/report2016](http://www.sobi.com/report2016).

#### **Swedish Orphan Biovitrum AB (publ)**

Postal address SE-112 76 Stockholm, Sweden

Phone: +46 697 20 00 [www.sobi.com](http://www.sobi.com)

**For more information please contact**

Media relations

Linda Holmström, Senior Communications Manager

+ 46 708 73 40 95, + 46 8 697 31 74

[linda.holmstrom@sobi.com](mailto:linda.holmstrom@sobi.com)

Investor relations

Jörgen Winroth, Vice President, Head of Investor Relations

+1 347 224 0819, +1 212 579 0506, +46 8 697 2135

[jorgen.winroth@sobi.com](mailto:jorgen.winroth@sobi.com)